Clinical Trials Browser

Interventional × darolutamide × 30 days × Clear all

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06378866 2026-04-20

DIVINE

Phase 2 Recruiting

532 enrolled

Genitourinary

Prostatic Neoplasms

NCT05794906 2026-04-17

ARASTEP

Phase 3 Active not recruiting

985 enrolled

Genitourinary

Biochemically Recurrent Prostate Cancer

NCT04464226 2026-04-15

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Phase 3 Active not recruiting

402 enrolled

Tumor-Agnostic

Neoplasms

NCT06220864 2026-04-14

SNV1521 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

400 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06592924 2026-04-14

TRIPLE-SWITCH

Phase 3 Recruiting

830 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07450599 2026-04-14

CHINANEO

Phase 2 Not yet recruiting

250 enrolled

Genitourinary

High-Risk Localized Prostate Cancer

NCT05818683 2026-04-13

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Phase 1 Recruiting

300 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT06169124 2026-04-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Phase 2 Active not recruiting

37 enrolled

Granulosa cell tumor of the ovary

NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

54 enrolled

Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT05050084 2026-04-08

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Phase 3 Active not recruiting

2,050 enrolled

Genitourinary

Prostate Adenocarcinoma

NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase 2 Completed

57 enrolled

Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07190300 2026-04-08

TulmiSTAR-02

Phase 1/2 Recruiting

155 enrolled

Bulbo-Spinal Atrophy, X-Linked

NCT06120491 2026-04-03

EvoPAR-PR01

Phase 3 Recruiting

1,800 enrolled

Genitourinary

Prostatic Neoplasms

NCT05059236 2026-04-02

ARASEC

Phase 2 Active not recruiting

223 enrolled

Genitourinary

Prostatic Neoplasms

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

25 enrolled

Genitourinary

Prostatic Neoplasms

NCT06401980 2026-03-30

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 2 Recruiting

162 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

Clinical Trials

AMX-500

DIVINE

ARASTEP

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

SNV1521 in Participants With Advanced Solid Tumors

TRIPLE-SWITCH

CHINANEO

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

TulmiSTAR-02

EvoPAR-PR01

ARASEC

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)